ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Position Lowered by Royce & Associates LP

Royce & Associates LP lowered its position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 30.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 642,766 shares of the company's stock after selling 286,847 shares during the quarter. Royce & Associates LP owned 0.65% of ARS Pharmaceuticals worth $8,086,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter worth $27,000. ANTIPODES PARTNERS Ltd acquired a new position in shares of ARS Pharmaceuticals in the 1st quarter valued at $37,000. KLP Kapitalforvaltning AS acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $73,000. BNP Paribas Financial Markets purchased a new position in ARS Pharmaceuticals in the 4th quarter worth about $75,000. Finally, Ball & Co Wealth Management Inc. acquired a new stake in ARS Pharmaceuticals during the 4th quarter worth about $105,000. 68.16% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, CFO Kathleen D. Scott sold 50,000 shares of the stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $14.10, for a total value of $705,000.00. Following the completion of the sale, the chief financial officer owned 7,424 shares in the company, valued at $104,678.40. This represents a 87.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Karas sold 15,000 shares of the company's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $16.99, for a total transaction of $254,850.00. Following the completion of the transaction, the insider directly owned 10,315 shares in the company, valued at $175,251.85. This trade represents a 59.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,043,118 shares of company stock worth $18,024,863. 33.50% of the stock is owned by company insiders.

ARS Pharmaceuticals Stock Down 0.3%

NASDAQ:SPRY opened at $17.87 on Friday. The business's fifty day moving average price is $16.10 and its 200 day moving average price is $13.89. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -111.68 and a beta of 0.90. The company has a current ratio of 11.00, a quick ratio of 10.74 and a debt-to-equity ratio of 0.30. ARS Pharmaceuticals, Inc. has a 1-year low of $8.91 and a 1-year high of $18.90.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.35). The company had revenue of $7.97 million for the quarter, compared to the consensus estimate of $7.48 million. ARS Pharmaceuticals had a negative return on equity of 6.94% and a negative net margin of 16.11%. On average, sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen cut shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $31.00.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

Want to see what other hedge funds are holding SPRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.